Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Antimicrobial Chemotherapy for Legionnaires' Disease: A Review

Paul H. Edelstein
Clinical Infectious Diseases
Vol. 21, Supplement 3. Bacterial Pneumonia: Pathogenesis, Pathogens, Diagnosis, and Treatment (Dec., 1995), pp. S265-S276
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4459154
Page Count: 12
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Antimicrobial Chemotherapy for Legionnaires' Disease: A Review
Preview not available

Abstract

Controlled trials of antimicrobial chemotherapy for legionnaires' disease have not been performed, although erythromycin and tetracycline appear to be effective therapies. Laboratory data indicate that the activities of the fluoroquinolone and newer macrolide/azalide agents against Legionella pneumophila are superior to that of erythromycin, and case reports substantiate that the activities of these agents are at least equal. Results of clinical treatment with and laboratory testing of macrolides, tetracyclines, co-trimoxazole, chloramphenicol, aminoglycosides, fluoroquinolones, β-lactam agents, and streptogramins are reviewed. The drugs of choice for the treatment of legionnaires' disease in immunocompromised or severely ill patients should be one of the fluoroquinolone antimicrobials rather than erythromycin.

Page Thumbnails

  • Thumbnail: Page 
S265
    S265
  • Thumbnail: Page 
S266
    S266
  • Thumbnail: Page 
S267
    S267
  • Thumbnail: Page 
S268
    S268
  • Thumbnail: Page 
S269
    S269
  • Thumbnail: Page 
S270
    S270
  • Thumbnail: Page 
S271
    S271
  • Thumbnail: Page 
S272
    S272
  • Thumbnail: Page 
S273
    S273
  • Thumbnail: Page 
S274
    S274
  • Thumbnail: Page 
S275
    S275
  • Thumbnail: Page 
S276
    S276